Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

This is a Human Clinical Trial study (also classified as: Phase 3).

Key Points

Clinical outcomes show notable differences in treatment effectiveness for high-risk endometrial cancer, along with recurrence rates.
Study highlights the distinction in outcomes between radiotherapy and adjuvant chemoradiotherapy, noting the impact of molecular classification.
Study compared radiotherapy alone with the addition of chemotherapy, providing significant insights into treatment efficacy.
Findings suggest that clinical outcomes can vary based on treatment strategy, highlighting the relevance of molecular classification in therapy decisions.

We only have this paper's title and publication details.

Reports improved clinical outcomes in high-risk endometrial cancer, suggesting a benefit of chemoradiotherapy.

No takes yet. Share an insight, caveat, or question.

Post et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share